Last 7 days
-5.4%
Last 30 days
47.0%
Last 90 days
5.4%
Trailing 12 Months
-25.9%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 442.1B | 96.0B | -4.77% | 1.21% | 23.08 | 4.6 | 5.02% | 7.14% |
LLY | 308.1B | 29.2B | -6.33% | 46.49% | 51.07 | 10.54 | 5.34% | 1.02% |
MRK | 267.0B | 59.0B | -5.13% | 34.98% | 17.49 | 4.53 | 27.84% | 112.03% |
PFE | 245.5B | 99.9B | -13.80% | -15.92% | 8.25 | 2.46 | 45.01% | 53.21% |
BMY | 154.0B | 46.7B | 0.64% | 15.96% | 23.07 | 3.3 | 2.79% | 223.53% |
MID-CAP | ||||||||
PRGO | 5.0B | 4.4B | 10.03% | -0.57% | -46.66 | 1.14 | 1.80% | 57.67% |
SUPN | 2.2B | 659.0M | 13.79% | 40.18% | 57.51 | 3.29 | 16.78% | -53.92% |
SMALL-CAP | ||||||||
TLRY | 1.9B | 613.6M | 24.42% | -38.51% | -3.79 | 3.14 | 37.73% | -7.19% |
RETA | 1.6B | 3.1M | 23.90% | 79.89% | -5.08 | 503.44 | -77.09% | -12.24% |
CGC | 1.4B | - | 33.79% | -57.23% | -0.46 | 1.95 | -4.11% | -144.36% |
ACRS | 1.2B | 23.5M | 12.85% | 73.07% | -14.2 | 49.6 | 243.57% | -1.04% |
CRON | 942.1M | 112.7M | - | -24.55% | -4.21 | 8.36 | 45.53% | 40.26% |
INVA | 885.5M | - | -2.61% | -19.99% | 2.65 | 2.34 | 10.49% | -16.07% |
OCUL | 298.8M | 49.7M | 46.97% | -25.95% | -5.03 | 6.01 | 28.95% | 32.80% |
ENDP | 94.1M | 2.6B | -43.99% | -88.43% | -0.03 | 0.04 | -13.88% | -4855.92% |
Income Statement (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Revenue | -0.4% | 49,726 | 49,914 | 49,366 | 43,522 | 38,562 |
S&GA Expenses | 1.6% | 38,525 | 37,915 | 36,166 | 35,190 | 32,864 |
R&D Expenses | 1.9% | 52,497 | 51,497 | 52,256 | 50,083 | 45,129 |
Interest Expenses | 2.1% | 6,856 | 6,717 | 6,676 | 6,671 | 6,718 |
Net Income | -82.6% | -59,346.00 | -32,501.00 | -22,216.00 | -6,553.00 | -88,315.00 |
Net Income Margin | -83.3% | -1.19* | -0.65* | -0.45* | -0.15* | - |
Free Cahsflow | -1.2% | -59,994.00 | -59,289.00 | -68,103.00 | -66,744.00 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Assets | -8.4% | 159 | 173 | 188 | 205 | 218 |
Current Assets | -9.2% | 146 | 160 | 175 | 191 | 204 |
Cash Equivalents | -10.1% | 121 | 135 | 145 | 164 | 179 |
Inventory | 3.0% | 2 | 2 | 1 | 1 | 1 |
Net PPE | 7.7% | 7 | 7 | 7 | 7 | 7 |
Liabilities | 4.7% | 112 | 107 | 108 | 117 | 130 |
Current Liabilities | 12.1% | 29 | 26 | 24 | 26 | 25 |
Shareholder's Equity | -29.7% | 46 | 66 | 80 | 88 | 87 |
Retained Earnings | -4.2% | -601.30 | -577.11 | -558.35 | -545.80 | -541.95 |
Additional Paid-In Capital | 0.7% | 648 | 643 | 638 | 634 | 629 |
Accumulated Depreciation | - | 15 | - | - | - | - |
Shares Outstanding | 0.1% | 77 | 77 | 77 | 77 | 77 |
Cashflow (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Cashflow From Operations | -0.3% | -57,798.00 | -57,611.00 | -66,791.00 | -65,550.00 | -56,643.00 |
Share Based Compensation | 3.0% | 16,571 | 16,089 | 16,100 | 14,977 | 13,240 |
Cashflow From Investing | -30.9% | -2,196.00 | -1,678.00 | -1,312.00 | -1,194.00 | -816.00 |
Cashflow From Financing | -15.5% | 1,663 | 1,968 | 4,142 | 2,851 | 166,097 |
98.8%
97.3%
72.3%
Y-axis is the maximum loss one would have experienced if Ocular Therapeutix was unfortunately bought at previous high price.
-6.3%
-5.7%
-4.2%
FIve years rolling returns for Ocular Therapeutix.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-01-26 | STRS OHIO | unchanged | - | -21,000 | 44,000 | -% |
2023-01-25 | Hikari Power Ltd | unchanged | - | -23,000 | 48,000 | -% |
2023-01-25 | DELTEC ASSET MANAGEMENT LLC | reduced | -20.26 | -4,436,220 | 5,206,780 | 1.49% |
2023-01-25 | Lindbrook Capital, LLC | sold off | -100 | -3,000 | - | -% |
2023-01-24 | Centerpoint Advisors, LLC | unchanged | - | -4,000 | 10,000 | -% |
2023-01-19 | Quent Capital, LLC | new | - | 1,377 | 1,377 | -% |
2023-01-18 | Verition Fund Management LLC | added | 100 | 43,000 | 84,000 | -% |
2023-01-13 | BEACON INVESTMENT ADVISORY SERVICES, INC. | unchanged | - | -16,280 | 33,720 | -% |
2023-01-09 | Founders Capital Management | unchanged | - | -3,000 | 7,000 | -% |
2023-01-06 | MASSMUTUAL TRUST CO FSB/ADV | added | 75.41 | - | - | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 03, 2022 | blackrock inc. | 6.7% | 5,122,835 | SC 13G/A | |
Feb 01, 2022 | opaleye management inc. | 7.80% | 5,974,800 | SC 13G/A | |
Feb 12, 2021 | opaleye management inc. | 8.65% | 9 | SC 13G/A | |
Feb 02, 2021 | blackrock inc. | 7.3% | 5,512,264 | SC 13G | |
Jun 09, 2020 | blackrock inc. | 4.8% | 3,006,167 | SC 13G/A | |
May 21, 2020 | summer road llc | 17.0% | 11,387,656 | SC 13D/A | |
Mar 25, 2020 | summer road llc | 18.9% | 11,024,020 | SC 13D/A | |
Feb 14, 2020 | versant side fund iii, l.p. | 0.1% | 13,007 | SC 13G/A | |
Feb 10, 2020 | man group plc | 1.58% | 760,490 | SC 13G/A | |
Feb 05, 2020 | blackrock inc. | 5.9% | 2,829,644 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Jan 06, 2023 | 8-K | Current Report | |
Nov 09, 2022 | 4 | Insider Trading | |
Nov 07, 2022 | 8-K | Current Report | |
Nov 07, 2022 | 10-Q | Quarterly Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2022-11-07 | SUMMER ROAD LLC | bought | 25,648 | 3.5 | 7,328 | - |
2022-10-11 | SUMMER ROAD LLC | bought | 38,993 | 3.8993 | 10,000 | - |
2022-10-10 | SUMMER ROAD LLC | bought | 39,982 | 3.9982 | 10,000 | - |
2022-09-29 | SUMMER ROAD LLC | bought | 75,987.7 | 4.0419 | 18,800 | - |
2022-09-28 | SUMMER ROAD LLC | bought | 4,920 | 4.1 | 1,200 | - |
2022-09-27 | SUMMER ROAD LLC | bought | 608,322 | 4.6794 | 130,000 | - |
2022-07-01 | Ozden Rabia Gurses | acquired | - | - | 6,667 | chief medical officer |
2022-06-16 | Warden Charles M | acquired | - | - | 8,933 | - |
2022-06-16 | Heier Jeffrey S. | acquired | - | - | 8,933 | - |
2022-06-16 | RAINES MERILEE | acquired | - | - | 8,933 | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenue: | ||||
Total revenue, net | $ 11,965 | $ 12,153 | $ 37,419 | $ 31,214 |
Costs and operating expenses: | ||||
Cost, Product and Service [Extensible List] | Product | Product | Product | Product |
Cost of product revenue | $ 1,073 | $ 1,310 | $ 3,528 | $ 3,298 |
Research and development | 13,719 | 12,719 | 39,919 | 37,505 |
Selling and marketing | 10,186 | 9,576 | 29,390 | 26,054 |
General and administrative | 8,531 | 8,077 | 23,875 | 24,345 |
Total costs and operating expenses | 33,509 | 31,682 | 96,712 | 91,202 |
Loss from operations | (21,544) | (19,529) | (59,293) | (59,988) |
Other income: | ||||
Interest income | 285 | 7 | 375 | 27 |
Interest expense | (1,797) | (1,658) | (5,175) | (4,991) |
Change in fair value of derivative liability | (1,133) | 23,837 | 8,598 | 62,249 |
Other income (expense), net | 1 | (1) | ||
Total other income, net | (2,644) | 22,186 | 3,797 | 57,285 |
Net (loss) income | $ (24,188) | $ 2,657 | $ (55,496) | $ (2,703) |
Net (loss) income per share, basic | $ (0.31) | $ 0.03 | $ (0.72) | $ (0.04) |
Weighted average common shares outstanding, basic | 76,975,839 | 76,552,060 | 76,829,434 | 76,317,563 |
Net (loss) income per share, diluted | $ (0.31) | $ (0.23) | $ (0.73) | $ (0.75) |
Weighted average common shares outstanding, diluted | 76,975,839 | 85,446,886 | 82,598,666 | 82,086,795 |
Product | ||||
Revenue: | ||||
Total revenue, net | $ 11,913 | $ 12,153 | $ 36,555 | $ 31,214 |
Collaboration revenue | ||||
Revenue: | ||||
Total revenue, net | $ 52 | $ 864 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 120,950 | $ 164,164 |
Accounts receivable, net | 19,802 | 21,135 |
Inventory | 1,545 | 1,250 |
Prepaid expenses and other current assets | 3,318 | 4,751 |
Total current assets | 145,615 | 191,300 |
Property and equipment, net | 7,196 | 6,956 |
Restricted cash | 1,764 | 1,764 |
Operating lease assets | 4,004 | 4,867 |
Total assets | 158,579 | 204,887 |
Current liabilities: | ||
Accounts payable | 5,308 | 4,592 |
Accrued expenses and other current liabilities | 21,614 | 20,121 |
Deferred revenue | 603 | |
Operating lease liabilities | 1,744 | 1,624 |
Total current liabilities | 29,269 | 26,337 |
Other liabilities: | ||
Operating lease liabilities, net of current portion | 4,610 | 5,924 |
Derivative liability | 11,594 | 20,192 |
Deferred revenue, net of current portion | 13,533 | 13,000 |
Notes payable, net of discount | 25,192 | 25,000 |
2026 convertible notes, net | 28,152 | 26,435 |
Total liabilities | 112,350 | 116,888 |
Commitments and contingencies | ||
Stockholders' equity: | ||
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at September 30, 2022 and December 31, 2021, respectively | ||
Common stock, $0.0001 par value; 200,000,000 shares authorized and 77,010,385 and 76,731,940 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively | 8 | 8 |
Additional paid-in capital | 647,521 | 633,795 |
Accumulated deficit | (601,300) | (545,804) |
Total stockholders' equity | 46,229 | 87,999 |
Total liabilities and stockholders' equity | $ 158,579 | $ 204,887 |